What is AbbVie's qulipta — net revenues?

AbbVie (ABBV) reported qulipta — net revenues of $296M in Q1 2026.

How has AbbVie's qulipta — net revenues changed year-over-year?

AbbVie's qulipta — net revenues increased by 53.4% year-over-year, from $193M to $296M.

What does qulipta — net revenues mean?

This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowances, and rebates. It serves as a key indicator of the product's market adoption, competitive positioning in the neurology or migraine treatment space, and its contribution to the company's overall top-line growth. Tracking this revenue stream helps investors assess the commercial success of the drug following its regulatory approval and launch phase.

AbbVie ABBV Qulipta — Net revenues

Other product segments

Skyrizi

$4.48B+30.9%

Rinvoq

$2.12B+23.3%

All other

$1.03B-18.2%

Botox Therapeutic

$1.01B+16.5%

Vraylar

$905M+18.3%

Venclexta

$770M+15.8%

Humira

$688M-38.6%

Botox Cosmetic

$668M+20.1%

Imbruvica

$556M-24.7%

Mavyret

$351M+14.7%

Ubrelvy

$339M+41.3%

Other Aesthetics

$286M-9.2%

Linzess

$283M+91.2%

Juvederm Collection

$232M+0.4%

Vyalev

$201M+219%

Elahere

$198M+10.6%

Other Neuroscience

$125M-19.4%

Epkinly

$83M+62.7%

Similar metrics at other companies

SUPNQelbree — Total revenues

$77.84M+20.2%

ESP

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

PFEEliquis — Revenues:

$2.17B+12.6%

TARSProduct sales, net — Total revenues

$145.39M+85.6%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

Other financials

Income statement

See full

Revenue$15.0B+12.4%

Gross profit$10.8B+15.4%

Operating income$4.0B+6.9%

Net income$695.0M-46.0%

EPS (diluted)$0.39-45.8%

Balance sheet

See full

Cash & equivalents$9.4B+81.5%

Total debt$62.4B+1.8%

Total equity-$6.7B-569%

Total assets$136.46B+0.2%

Cash flow

See full

Operating cash flow$3.8B+134%

CapEx$265.0M+12.8%

Free cash flow$3.6B+155%

Valuation

See full

Market cap$465.2B+39.1%

P/E128×+39.1×

P/S7.4×+1.7×

Profitability

See full

Gross margin70.7%0.0pp

Operating margin24.4%—

Net margin5.8%-1.5pp

FCF margin31.8%+5.0pp

Returns & leverage

See full

Return on equity89%+32.7pp

Debt / equity46.6×+38.6×

Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's qulipta — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbbVie's qulipta — net revenues?: AbbVie (ABBV) reported qulipta — net revenues of $296M in Q1 2026.
How has AbbVie's qulipta — net revenues changed year-over-year?: AbbVie's qulipta — net revenues increased by 53.4% year-over-year, from $193M to $296M.
What does qulipta — net revenues mean?: This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowances, and rebates. It serves as a key indicator of the product's market adoption, competitive positioning in the neurology or migraine treatment space, and its contribution to the company's overall top-line growth. Tracking this revenue stream helps investors assess the commercial success of the drug following its regulatory approval and launch phase.